Clinical Trial Update: Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

Phase III clinical trial evaluating rilvegostomig plus bevacizumab, with or without tremelimumab, as first-line therapy for hepatocellular carcinoma. The study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Rilvegostomig (rilvegostomig)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: RECRUITING